Novartis’ Kisqali (ribociclib) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat a ...

Novartis UK announced the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised ribociclib for adjuvant ...

Trainer to face charges for presenting horse to the races twice in 2024 with several banned substances in his system ...

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

The regulator approved the indication based on data showing Kisqali with an aromatase inhibitor improved invasive disease-free survival versus just an aromatase inhibitor.

Do innovator drugs work better than generic ... Ask the Pharmacists, November 2010 Can the Duration of Aromatase Inhibitor Therapy Exceed 5 Years? Does extended-duration aromatase inhibitor ...

Swiss pharma giant Novartis AG NVS reported better-than-expected results for the fourth quarter of 2024. Core earnings ...

Drug-related adverse events include hand ... Sorafenib might help overcome resistance to the aromatase inhibitors in patients with hormone receptor-positive MBC who have developed resistance ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA ... for Lilly to acquire Scorpion's PI3Kα inhibitor program STX-478. STX-478 is a once-daily ...

Patrick Payne, a Group 1-winning trainer, has been charged by Racing Victoria (RV) stewards after presenting a horse to the ...

Drugs called aromatase inhibitors, like one of the ones Eggert is taking, are used to block the activity of the aromatase enzyme and, therefore, stop the production of estrogen. This helps slow down ...

Discover the role of phytoestrogens, including soy, in menopause management and breast cancer prevention. Learn how these ...